Targeting SMPDL3B to Ameliorate Radiation- and Cisplatin-Induced Renal Toxicity
Authors:
- Anis AhmadAnis Ahmad
- Shamroop Kumar MallelaSMShamroop Kumar Mallela
- Saba AnsariSASaba Ansari
- Mohammed AlnukhaliMAMohammed Alnukhali
- Sandra MerscherSMSandra Merscher
- Alla MitrofanovaAlla Mitrofanova
- Youssef H. ZeidanYZYoussef H. Zeidan
- Alan PollackAPAlan Pollack
- Alessia FornoniAFAlessia Fornoni
- Brian MarplesBMBrian Marples
Open Access
Abstract
Kidney toxicity remains a major dose-limiting complication of radiation therapy and platinum-based chemotherapy, yet the molecular determinants of renal susceptibility and resilience to these genotoxic treatments are incompletely understood. Podocytes are particularly vulnerable to such insults, and emerging evidence implicates lipid dysregulation in podocyte injury. This study investigated the role of sphingomyelin phosphodiesterase acid-like 3B (SMPDL3B), a podocyte-enriched lipid-modulating enzyme, in radiation- and cisplatin-induced nephrotoxicity. Using a doxycycline-inducible, podocyte-specific SMPDL3B transgenic mouse model, renal injury was assessed following focal kidney irradiation, cisplatin administration, or their combination through functional assays, histopathology, ultrastructural analysis, immunofluorescence, and targeted lipidomics. Combined radiation and cisplatin exposure markedly reduced podocyte SMPDL3B expression, accompanied by podocyte depletion, glomerular basement membrane remodeling, proteinuria, and impaired renal function. These structural and functional abnormalities were associated with the selective accumulation of long-chain ceramide-1-phosphate species. In contrast, podocyte-specific induction of SMPDL3B preserved glomerular architecture, maintained renal function, and prevented pathological ceramide-1-phosphate elevation. Collectively, these findings identify SMPDL3B as a key regulator of podocyte stability and lipid homeostasis during chemoradiation stress. Enhancing SMPDL3B activity may represent a mechanistically grounded strategy to mitigate treatment-induced kidney injury while preserving anticancer efficacy.Keywords
Funding Information
- National Institutes of Health/National Cancer Institute Physical Sciences–Oncology Network Award (1R01CA227493)
- Live Like Bella Pediatric Cancer Research Initiative (9LA08)
- Live Like Bella Pediatric Cancer Research Initiative Program of the Florida Department of Health (23L12)
- U.S. Department of Defense Congressionally Directed Medical Research Kidney Cancer Research Programs (KC210133)
- University of Miami Sylvester Comprehensive Cancer Center Developmental Stanley J. Glaser Foundation Grant (UM SJG 2023-01)
- Sylvester Tumor Biology Intraprogrammatic Award (TB-INTRA-2024-03)
- Women’s Cancer Association FY2025 Award
- Veterans Administration Merit Review Award (BX-24-001)
This publication has 51 references indexed in Scilit:
- Therapeutic remodeling of the ceramide backbone prevents kidney injuryCell Metabolism, 2025
- First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysisCancer Treatment Reviews, 2025
- Drug delivery for platinum therapeuticsJournal of Controlled Release, 2025
- Radiation-Induced Nephrotoxicity: Role of Sphingomyelin Phosphodiesterase Acid-like 3bInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2024
- Nephrotoxicity in locally advanced head and neck cancer: when the end justifies the means to preserve nutritional status during chemoradiationSupportive Care in Cancer, 2024
- Cisplatin chemotherapy and renal function2021
- Endoplasmic Reticulum Stress Activates the Inflammasome via NLRP3- and Caspase-2-Driven Mitochondrial DamageImmunity, 2015
- Cisplatin in cancer therapy: Molecular mechanisms of actionEuropean Journal of Pharmacology, 2014
- Radiation-Associated Kidney InjuryInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- STRUCTURAL BIOLOGY OF THE FIBRES OF THE COLLAGENOUS AND ELASTIC SYSTEMSCell Biology International, 1996